The company has shut down the Veris molecular diagnostics product line, which Beckman Coulter spent years developing, as a result of its acquisition of Cepheid.
The assay is the firm homogeneous PCT assay for use on Beckman Coulter AU model chemistry analyzers and can be used to manage bacterial infections and sepsis.
The firm's European subsidiary is offering the new senior notes to repay, in part, all outstanding aggregate principal amounts on senior notes due later this month.
The investment bank took note of Danaher's soft organic growth rate in the first quarter, and said it will need to build up its life science portfolio.
Announced during the company's recent analyst day, the instrument could mark a major step in mass spectrometry's ongoing move into clinical applications.
The company beat Wall Street analysts' expectations for sales and earnings per share during the quarter.
The agency also cleared Roche's assay for diagnosing thyroid or pituitary disorders, as well as tests from Beckman Coulter, Immunostics, and BioMérieux.
A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.
Overall growth was driven by the company's diagnostics segment, which rose 11 percent, while life sciences improved 6 percent
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.